Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Industry News

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

February 26, 2018

News Industry News

REVA Receives CE Mark for Fantom

April 04, 2017

News Industry News

QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon

January 06, 2016

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Industry News

REVA Completes Clinical Enrollment Milestone

October 01, 2015

News Industry News

U.S. to vie with India for top bioabsorbable stent market after FDA approval

June 25, 2015

News Industry News

Elixir Medical Corporation Announces Successful Completion of First-In-Man Study Enrollment for Fully Bioresorbable Drug Eluting Coronary Scaffold System

November 02, 2011

Advertisement

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

REVA Receives CE Mark for Fantom

QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

REVA Completes Clinical Enrollment Milestone

U.S. to vie with India for top bioabsorbable stent market after FDA approval

Elixir Medical Corporation Announces Successful Completion of First-In-Man Study Enrollment for Fully Bioresorbable Drug Eluting Coronary Scaffold System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content